Tech Company Financing Transactions
RhyGaze Funding Round
GV, Arch Venture Partners and BioGeneration Ventures joined a $86 million Series A funding round for RhyGaze. The round was recorded on 1/13/2025.
Transaction Overview
Company Name
Announced On
1/13/2025
Transaction Type
Venture Equity
Amount
$86,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds for further development of its lead clinical candidate, a novel gene therapy for optogenetic vision restoration in diseases causing blindness.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Mittlere Strasse 91
Basel, 4031
Switzerland
Basel, 4031
Switzerland
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
RhyGaze is at the forefront of developing a novel gene therapy aimed at restoring vision in patients with blinding retinal diseases. RhyGaze AG, a spin-out from IOB, is developing a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Charles Gubser
Founder
Bence György
Founder
Botond Roska
Browse more venture capital transactions:
Prev: 1/13/2025: Truveta venture capital transaction
Next: 1/14/2025: FIZE Medical venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We report on tech company VC transactions. VC transactions reported here come from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs